Zhang, Bao-cun http://orcid.org/0000-0001-6104-0848
Laursen, Marlene F. http://orcid.org/0000-0002-2804-0026
Hu, Lili
Hazrati, Hossein
Narita, Ryo http://orcid.org/0000-0003-2045-2509
Jensen, Lea S.
Hansen, Aida S. http://orcid.org/0000-0002-6547-8393
Huang, Jinrong http://orcid.org/0000-0001-8085-9939
Zhang, Yan
Ding, Xiangning
Muyesier, Maimaitili
Nilsson, Emil http://orcid.org/0000-0001-9509-422X
Banasik, Agnieszka
Zeiler, Christina http://orcid.org/0000-0002-3006-9004
Mogensen, Trine H. http://orcid.org/0000-0002-1853-9704
Etzerodt, Anders http://orcid.org/0000-0002-6757-2068
Agger, Ralf http://orcid.org/0000-0002-1434-5726
Johannsen, Mogens http://orcid.org/0000-0002-2548-7025
Kofod-Olsen, Emil
Paludan, Søren R. http://orcid.org/0000-0001-9180-4060
Jakobsen, Martin R. http://orcid.org/0000-0001-8847-9201
Article History
Received: 24 May 2023
Accepted: 18 March 2024
First Online: 29 March 2024
Competing interests
: M.R.J. is shareholder within STipe Therapeutics that develop cancer immunotherapies targeting the STING pathway. The remaining authors declare no competing interests.